Eli Lilly said it received Food and Drug Administration approval for its treatment for moderate to severely-active Crohn’s ...

Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company committed to developing novel drugs targeting ...

Omvoh (mirikizumab-mrkz) for moderately to severely active Crohn’s disease in adults. Omvoh is now approved in the U.S. for ...

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second ...

Eli Lilly has claimed FDA approval for its IL-23 inhibitor Omvoh as a treatment for moderately to severely active Crohn's ...

UK scientists have made a major breakthrough while investigating inflammatory bowel disease, which could change the lives of ...

A study suggests that adjunct therapies, including the Mediterranean diet, physical activity, and cognitive behavioral ...

Eli Lilly and Co. (LLY) announced that the U.S. Food and Drug Administration has approved Omvoh (mirikizumab-mrkz) for the treatment ...

Current treatments for IBD are limited. They don't cure the disease and patients require ongoing treatment. High rates of people don't respond to treatments or lose responsiveness over time, so it's ...

New Inflammatory Bowel Disease Testing Protocol Could Speed ... 2024 — A large-scale clinical trial of treatment strategies for Crohn's disease has shown that offering early advanced therapy ...

Odyssey Therapeutics (ODTX), which is developing treatments for inflammatory bowel disease, has filed for a $100M initial ...